Drug intelligence / Profile preview

64B

Development stage: Preclinical
Lead developer: OncoSpherix
Modality: Small Molecules

Overview

64B is a small molecule inhibitor developed by OncoSpherix that targets the interaction between the transcriptional co-activators p300/CBP and the transcription factor Hypoxia-inducible factor 1-alpha (HIF-1α). By disrupting this interaction, 64B inhibits the expression of genes regulated by HIF-1α, which are critical for tumor adaptation to hypoxic environments, angiogenesis, and metabolic reprogramming. The drug is currently in IND-enabling studies for the treatment of various solid tumors, including glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, and breast cancer.

Targets

EP300 (Histone acetyltransferase p300)

Beyond the preview

Go deeper on 64B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 64B.

Explore the full profile